Get the Stockscreener App
145.55
2.23%
-3.32
After Hours:
145.00
-0.55
-0.38%
Moderna Inc stock is traded at $145.55, with a volume of 14.92M.
It is down -2.23% in the last 24 hours and up +155.40% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$148.87
Open:
$153.62
24h Volume:
14.92M
Relative Volume:
1.00
Market Cap:
$58.11B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-17.87
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+5.48%
1M Performance:
+155.40%
6M Performance:
+151.82%
1Y Performance:
+499.46%
1-Day Range:
$141.52
$154.69
1-Week Range:
$133.85
$156.42
52-Week Range:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Inc. stock gains strongly as cancer vaccine partnership fuels rally - AD HOC NEWS
Moderna Stock (MRNA) Opinions on Melanoma Vaccine Trial Results - Quiver Quantitative
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks - Yahoo Finance
Moderna, Inc. (MRNA) Stock Analysis: Is the Biotech Giant’s Market Cap Justified Amid a 19.96% Potential Downside? - DirectorsTalk Interviews
Alibaba DAMO Academy's Liver Cancer AI Model Tops Nature Medicine; Clinical Trial Catches 15 Missed Diagnoses - finance.biggo.com
Moderna Expands mRNA Territory Beyond Personalized Cancer Vaccines to Universal Shots and In Vivo CAR-T - finance.biggo.com
Moderna Moves Beyond Personalized Cancer Vaccines to Universal Shot - Seoul Economic Daily
Moderna Inc. stock holds steady as investors watch vaccine revenue and oncology pipeline - AD HOC NEWS
MRNA Looks 503.7% Overvalued on GF Value™ - GuruFocus
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - MarketBeat
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.) - Yahoo Finance
AlphaGrep UK Ltd Invests $568,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakABC News - ABC News - Breaking News, Latest News and Videos
MRNA Looks 503.4% Overvalued on GF Value™ - GuruFocus
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks - Seeking Alpha
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
Step Capital Management Pte. Ltd. Has $48.67 Million Stake in Moderna, Inc. $MRNA - MarketBeat
22,477 Shares in Moderna, Inc. $MRNA Acquired by AXQ Capital LP - MarketBeat
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. - WSJ
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth? - Yahoo Finance
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes? - Yahoo Finance
Moderna's mRNA flu vaccine, mFlusiva, offers option for adults 50-64 with potential benefits over traditional shot - ABC7 New York
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run - Yahoo Finance
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run? - Yahoo Finance
Healthcare Stocks To Watch TodaySeptember 4th - MarketBeat
Moderna stock falls after Rothschild Redburn downgrade - AD HOC NEWS
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says - Yahoo! Finance Canada
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Moderna (MRNA) Stock Is Down Today - Yahoo Finance
Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says - CNBC TV18
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? - The Globe and Mail
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets - FXEmpire
Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock - MarketBeat
Moderna (MRNA) CFO has 2,475 stock units vest in Sept. award - Stock Titan
Moderna (MRNA) legal chief trades stock under 10b5-1 plan - Stock Titan
MRNA Looks 500.3% Overvalued on GF Value™ - GuruFocus
Can Moderna reclaim 52-week highs after pullback, or have best levels been seen? - Investing.com
Moderna stock slips as Rothschild downgrades (MRNA:NASDAQ) - Seeking Alpha
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop - Barron's
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK? - Yahoo Finance
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade - MarketBeat
MRNA Downgraded by Rothschild & Co -- Price Target Raised to $81 - GuruFocus
Rothschild & Co Redburn Downgrades Moderna (NASDAQ:MRNA) to Sell - MarketBeat
Moderna: Massive Asymmetry About What The mRNA Is! (NASDAQ:MRNA) - Seeking Alpha
Rothschild Redburn downgrades Moderna stock on valuation concerns By Investing.com - Investing.com India
A cancer vaccine is closer than ever - themalaysianreserve.com
Jim Cramer Explains Why Heavily Shorted Moderna (MRNA) Has Room to Run - Yahoo Finance
MRNA Stock Pulls Back to $150 as Moderna Faces Key Test Ahead - FXLeaders
Why Moderna's Cancer Vaccine Matters To Investors - ETF Database
Moderna Stock Moves Lower Wednesday: What's Going On? - Benzinga
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 01 '26 |
Sale |
139.95 |
3,471 |
485,766 |
74,129 |
1.93%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):